估算非小细胞肺癌的姑息性放疗需求:一种基于标准的基准设定方法
研究基于安大略省人群癌症登记,纳入2006至2010年死于非小细胞肺癌的患者,通过多因素分析确定姑息性放疗利用的影响因素,以诊断医院具备现场放疗能力者定义基准人群。标准化后基准人群临终前2年内接受姑息性放疗的比例为56%,全省实际比例为49%。结论认为约56%死于非小细胞肺癌的患者需要姑息性放疗,但许多患者从未接受治疗。
要点
- 诊断医院具备现场放疗能力是姑息性放疗利用增加的主要决定因素。
- 标准化后基准人群临终前2年内姑息性放疗比例为56%,全省为49%。
- 实际与最优比例之间的差距随患者年龄、治疗指征和地理区域而异。
核心结论
- 在安大略省,约56%死于非小细胞肺癌的患者需要姑息性放疗,但许多患者从未接受治疗。
研究设计与样本
- 基于安大略省人群癌症登记,识别2006至2010年死于非小细胞肺癌的患者。
- 采用多因素分析确定影响姑息性放疗利用的因素,以诊断医院具备现场放疗能力者定义基准人群,并将临终前2年内接受姑息性放疗的比例标准化至总体人群特征。
主要发现
- 诊断医院具备现场放疗能力是姑息性放疗利用增加的主要决定因素。
- 标准化后基准人群临终前2年内姑息性放疗比例为56%,全省实际比例为49%。
- 实际与最优比例之间的差距随患者年龄、治疗指征和地理区域而异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Estimates of appropriate treatment rates are required for monitoring and improving access to cancer care. Optimal utilization rates for palliative radiotherapy (PRT) for patients with non-small cell lung cancer (NSCLC) remain undefined. We aim to estimate the appropriate PRT rate for the general NSCLC population. MATERIALS AND METHODS: Ontario's population-based cancer registry identified patients with NSCLC who died of their disease between 2006 and 2010. Multivariate analysis identified factors affecting PRT use, enabling us to define a benchmark population with unimpeded access to PRT. Proportion of cases treated in the last 2 years of life (PRT2y) was standardized to overall population characteristics. Benchmarks were compared to province-wide PRT2y rates. RESULTS: Availability of RT at the diagnosing hospital was the dominant determinant of increased PRT utilization. Patients diagnosed at hospitals with on site RT were therefore designated the benchmark population. The standardized benchmark for PRT2y was 56%, compared to the province-wide rate of 49%. The gap between actual and optimal rates varied across patient ages, treatment indications, and geographic regions. CONCLUSIONS: Approximately 56% of patients who die of NSCLC in Ontario need PRT, but many are never treated.
引用
- Jin CJ, Kong W, Mackillop WJ, et al. Estimating the need for palliative radiotherapy for non-small cell lung cancer: A criterion-based benchmarking approach. Radiother Oncol. 2018. PMID: 29934108. doi:10.1016/j.radonc.2018.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。